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Molecular detection of Tropheryma whipplei is an important tool in the diagnosis 
of Whipple’s Disease and other T. whipplei infections. This thesis describes the design 
and validation of a real-time polymerase chain reaction assay that detects T. whipplei in 
cerebrospinal fluid, whole blood, tissue, formalin-fixed paraffin-embedded tissue, serum, 
and plasma samples. The assay detects a repeated sequence present seven times in the T. 
whipplei genome and the rpoB gene in a multiplex format. The assay is highly specific 
for T. whipplei and is capable of detecting less than four copies per PCR reaction with 
certain sample types. The validated assay has been in use at ARUP Laboratories since 
April 2016 and has detected T. whipplei in three patient samples. 
This thesis also describes a method for manufacturing formalin-fixed paraffin-
embedded blocks containing cultured bacteria as a means of simulating positive patient 
samples when genuine positive samples are not available. However, quantification of the 
number of bacteria in a sample using this method requires postextraction quantification of 
target copy number. Digital polymerase chain reaction is capable of absolute 
quantification of a target sequence without reference to a standard curve and was used to 
quantify target copy number in manufactured formalin-fixed paraffin-embedded samples.  
The World Health Organization produces International Standards which serve as a 
common calibration material for many types of diagnostic testing. This includes several 
quantification standards for various pathogens which are quantified by molecular 
iv 
methods. However, these standards are not well characterized in terms of true copy 
number and nucleic acid sequence, which can lead to discordant results between 
molecular assays targeting different regions of a given pathogen’s genome. This thesis 
also describes the use of digital polymerase chain reaction to evaluate the World Health 
Organization 1st International Standard for Epstein-Barr virus and the World Health 
Organization 1st International Standard for Hepatitis D virus. This provides better 











“A small gland which was preserved in 15 per cent formalin and stained by the Levaditi 
method, showed some very peculiar structures. Studied with 1/12 objective these sections 
show great numbers of a rod-shaped organism. . . . Whether this is the active agent in this 
peculiar pathological complex cannot be determined from the study of this single case, 
but its distribution in the glands is very suggestive.” 
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Whipple’s Disease and Tropheryma whipplei 
Traditional biochemical methods for identifying bacteria rely on culturing 
organisms present in a clinical sample. While these methods are useful and remain an 
important part of laboratory medicine, biochemical identification is of limited use when 
the organism cannot be grown readily in the laboratory or is hazardous to routinely 
isolate. Examples of such bacteria include Rickettsia spp., Erhlichia spp., Bartonella spp., 
Coxiella burnetii, and Tropheryma whipplei. Infections caused by these organisms are 
increasingly identified by molecular methods (1).  
T. whipplei is a gram-positive member of the actinobacteria family. The 925,938 
base pair genome of T. whipplei is smaller than most actinobacteria and several genes 
involved in amino acid biosynthesis and other metabolic pathways are absent, 
contributing to its fastidious growth requirements (2). Humans are the only known 
reservoir, with bacteria usually residing in macrophages. Whether T. whipplei can 
replicate outside of cells has been debated, but its strict growth requirements suggest that 
the organism is typically intracellular (3). 
T. whipplei is the causative agent of Whipple’s Disease (WD). WD is named after 
George Hoyt Whipple, who described the disease in 1907 in a 36-year-old male. The 
patient had several years history of arthritis in multiple joints followed later by weight 
loss, cough, fever, loss of strength, and diarrhea. The patient was admitted to Johns 
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Hopkins Hospital with some suspicion of a tuberculosis infection—though no laboratory 
evidence of tuberculosis was found—and expired one month after admission. Dr. 
Whipple performed an exhaustive postmortem investigation on the patient during which 
he observed a rod-shaped organism in the macrophages of a glandular tissue sample (4). 
The disease was tentatively named Intestinal Lipodystrophy due to the accumulation of 
fat in the intestine and feces, but later became known as Whipple’s Disease. The cause of 
the patient’s illness was not known, though a bacterial etiology was considered possible 
based on Dr. Whipple’s observation of a rod-shaped organism.  
In 1949, periodic acid-Schiff (PAS) staining of tissues from WD patients showed 
macrophages containing inclusions similar to those observed by Dr. Whipple (5). Three 
years later, WD was successfully treated with antibiotics (6). In the 1960s, high-
resolution imaging by electron microscopy confirmed that the inclusions previously 
observed in WD biopsies were indeed bacteria with a characteristic trilamellar cell wall 
(7, 8). The bacterium became known as the Whipple’s Disease Associated Bacillus 
(WDAB) and was generally considered to be the cause of WD. However, WDAB could 
not be isolated in culture despite numerous attempts, leaving PAS staining as the primary 
tool for diagnosis. 
With advances in molecular testing methods in the 1980s and 1990s, polymerase 
chain reaction (PCR) could be used to identify bacteria directly from patient samples 
without the need for culturing. In 1991, broad-spectrum sequencing of bacterial 16S 
rRNA present in a small-bowel biopsy of a patient with WD produced a novel sequence 
that was ascribed to WDAB (9). The following year, 16S rRNA sequencing from several 
WD patients produced similar sequences and a specific PCR assay was designed to detect 
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the novel sequence. This assay was tested against samples from patients with and without 
WD, successfully identifying the affected patients (10). The bacterium was tentatively 
named Tropheryma whippelii, but was later changed to its current name of Tropheryma 
whipplei. 
 
Infections Caused by Tropheryma whipplei 
Classic WD is rare, with an estimated prevalence of 2–4 affected individuals per 
million people and an incidence of 1–6 cases per 10,000,000 people annually (11, 12). 
Approximately 98% of affected individuals are white and 73–90% are male, though more 
female cases have been identified in recent years (13, 14). The typical age at diagnosis is 
between 40 and 60 years old. 
The symptoms of WD vary significantly between cases. The name Tropheryma 
literally means “food barrier,” which refers to the malabsorption of nutrients and 
steatorrhea seen during WD. However, the initial presentation is usually rheumatoid 
factor negative polyarthritis (~73% of patients) which is intermittent and lasts for several 
years before additional symptoms appear. Diarrhea (81% of patients) and weight loss 
(93% of patients) typically appear next as the disease progresses (13). Brain lesions are 
present in up to 90% of patients and a wide variety of neurological symptoms are 
observed in 30% of all patients (3). Other symptoms can include abdominal pain, anemia, 
fever, cough, melanoderma, adenopathy, uveitis, and endocarditis (15, 16). WD is 
ultimately fatal if left untreated.  
WD can be very challenging to diagnose, with many patients waiting more than 
five years from their first complaint to a correct diagnosis (17). This is partially due to the 
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rarity of the disease, variation in its presentation, and the nonspecific character of its 
symptoms. Also, early symptoms of arthritis and arthralgia are commonly misdiagnosed 
as a form of rheumatic disease. These patients are often treated with glucocorticoids or 
anti-tumor necrosis factor alpha antibodies, both of which suppress the immune system 
and accelerate WD progression (18).  
Treatment for WD consists of antibiotic therapy lasting one to two years. 
Historically, ceftriaxone and meropenem were used for short-term treatment followed by 
long-term trimethoprim and sulfanomides (3). However, sulfanomide resistance has been 
demonstrated in several WD treatment failures and T. whipplei lacks the gene target for 
trimethoprim (19). Doxycycline combined with hydroxychloroquine are now 
recommended as a more effective therapy, with a sulfanomide added when there is 
neurological involvement (20). Recurrence of WD is not infrequent, affecting 5–30% of 
recovered individuals. These patients have a greater likelihood of experiencing 
neurological symptoms and have a worse prognosis (13). Lifetime antibiotic therapy may 
be necessary to prevent WD recurrence in high-risk cases.  
T. whipplei was originally thought to be a rare organism which causes a rare 
disease; however, the seroprevalence of T. whipplei antibodies in several adult 
populations is between 50–70%, indicating that exposure to T. whipplei is actually quite 
common (21). It is also estimated that 2–4% of the general population carry T. whipplei 
asymptomatically. It is also now known that T. whipplei causes several self-limiting acute 
infections. The best documented of these is a mild gastroenteritis in children, with 
complete clearance of the bacteria following the illness. T. whipplei can also cause self-
limiting bacteremia with fever and cough and may be a cause of pneumonia (22, 23). It is 
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believed that these kinds of mild infections account for the high seroprevalence of T. 
whipplei antibodies. 
T. whipplei is also a cause of chronic, localized infections. The most common of 
these is infectious endocarditis.  Various studies have estimated that T. whipplei causes 
between 2-6% of all cases of bacterial endocarditis and may be the most common cause 
of blood-culture negative endocarditis (24, 25). The presentation of T. whipplei 
endocarditis is atypical. Patients rarely meet the Duke criteria and blood cultures are 
consistently negative. PAS staining and molecular testing of heart valves are typically 
used to establish the diagnosis, though PCR of whole blood may also produce a positive 
result (25). T. whipplei has also been documented as a rare cause of encephalitis, chronic 
pulmonary infection, and uveitis (21). Infection in these compartments can also be seen 
in the context of classic WD. 
Why only a small number of people develop WD when exposure, carriage, and 
acute infections are common remains unclear. Fenollar et al. have suggested a general 
model of T. whipplei infections and WD where most individuals are exposed to T. 
whipplei during childhood and experience a mild acute infection or remain asymptomatic. 
The majority of these individuals clear the bacteria, but a subset become asymptomatic 
carriers of the organism. Of this group, a small number develop a poor immune response 
to T. whipplei and are unable to adequately control the bacterium, which eventually leads 
to WD as the person reaches middle-age (21). Why these individuals generate a poor 
immune response is unknown, but it has been hypothesized that a genetic defect may be 
responsible. This is supported by the high male-to-female ratio seen in WD, the near 
exclusive occurrence of WD in Caucasians, and the atypical cytokine profiles seen in WD 
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patients (26). However, such a genetic defect would have to be highly specific for T. 
whipplei as WD patients are not known to be more susceptible to other diseases. This 
suggests a more nuanced explanation for progression to WD which may involve a variety 
of factors, both genetic and environmental. 
 
Molecular Detection of Tropheryma whipplei 
Prior to the 1990s, diagnostic testing for WD relied on observation of the bacteria 
in patient samples. The first test for WD was PAS staining which enabled visualization of 
the bacteria as inclusions in macrophages from biopsies of the duodenum (5). However, 
Mycobacterium species and other bacteria are also visible in PAS-stained samples. 
Immunostaining for T. whipplei offers a more sensitive and specific alternative but is not 
widely available. Electron microscopy has also been used to visualize the characteristic 
trilamellar membrane of T. whipplei and diagnose WD, but the impracticality and lack of 
access to this method has limited its use. Western blot testing can be useful in 
differentiating between individuals with WD and asymptomatic carriers of T. whipplei. 
WD patients tend to produce a weaker reaction in this test, which is consistent with the 
impaired immune response to T. whipplei seen in individuals with WD. 
After the identification of T. whipplei in 1991, molecular testing for WD became 
possible. Early assays relied on sequencing the 16S rRNA gene for identification, but 
assay development quickly changed to real-time PCR (RT-PCR). Successful culturing of 
T. whipplei followed by genome sequencing identified additional genes which could be 
targeted in RT-PCR assays. The most common molecular targets used today are the 
DNA-directed RNA polymerase subunit beta (rpoB) gene and the molecular chaperone 
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groEL gene, as well as a unique repeat sequence of unknown function (7xRepeat) present 
seven times in the T. whipplei genome (27-29).  
Molecular testing for WD and other T. whipplei infections offers several 
advantages over staining methods, including increased sensitivity and specificity. 
Staining and other visual methods have low sensitivity, partially because T. whipplei is 
distributed unevenly in the duodenum and may not be present in high enough levels to be 
seen in a given biopsy. However, biopsies that are negative for T. whipplei by PAS 
staining can still test positive in molecular assays. RT-PCR also facilitates testing of 
liquid sample types such as whole blood, synovial fluid, cerebrospinal fluid (CSF), 
vitreous fluid, etc. These sample types are generally less sensitive for WD than 
duodenum tissue but have a high positive predictive value for WD and provide a less 
invasive alternative to biopsy when WD is suspected (30).  They can also be useful in 
identifying neurological involvement, the cause of arthritis during early stages of the 
disease, and in identifying localized infections such as infectious endocarditis and 
encephalitis. Molecular testing of saliva and stool can also be beneficial in ruling out 
classic WD. While asymptomatic carriers of T. whipplei and WD patients test positive in 
both sample types, a negative result in both saliva and stool has a near 100% negative 
predictive value for WD (30). 
This thesis describes the design and validation of a RT-PCR assay for the 
detection of T. whipplei. The assay was designed to detect multiple sequences within the 
T. whipplei genome simultaneously to provide greater confidence and confirmation of 
positive results with a second target. An approach to validating formalin-fixed paraffin-
embedded tissues is also described. 
8 
 
Quantification by Digital Polymerase Chain Reaction 
Accurate quantification of a target sequence is clinically significant for several 
pathogens. The usual approach for quantification in RT-PCR assays is to generate a 
standard curve using known quantities of organism. The World Health Organization 
(WHO) has produced several international standards for organisms such as Epstein-Barr 
virus (EBV), Cytomegalovirus, BK virus, Hepatitis C virus, etc., which serve as standard 
calibration material for generating standard curves at different laboratories. However, the 
concentration of these standards is expressed in international units (IUs), an arbitrary unit 
that does not have a defined relationship to the actual quantity of the organism in the 
standard. 
Digital PCR (dPCR) is a method for absolute quantification of a target sequence 
without reference to a standard curve. dPCR relies on partitioning the nucleic acid in a 
PCR reaction into thousands or millions of nano- to picoliter reactions. PCR 
amplification in each partition produces a digital result of amplification or no 
amplification based on whether target nucleic acid was present in the partition. The 
number of positive and negative partitions can then be used to calculated the number of 
target molecules present in the sample. 
Absolute quantification of WHO international standards by dPCR could enable 
the definition of these standards in terms of copies instead of IUs. This would enable 
simpler maintenance of the standard across generations and more accurate production of 
commercial secondary standards. This thesis describes the use of the QuantStudio 3D 
dPCR and RainDrop Plus dPCR systems to determine the target copy number of the 
WHO 1st International Standard for EBV and the WHO 1st International Standard for 
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Hepatitis D virus (HDV). The QuantStudio 3D system is also used to evaluate the 




MATERIALS AND METHODS 
  
In silico Methods 
Previously reported T. whipplei sequences were obtained from GenBank under 
the following accession and version numbers: NC_004572.3, NC_004551.1, EF536142.1, 
AE014184.1, AF243072.1, BX251410.1, AF483653.1, CAUY010000007.1, 
CAUR030000006.1, CAUF020000008.1, CAAG020000007.1, CAUQ020000006.1, 
CAAO020000008.1, CAVB010000005.1, CAUD020000005.1, CAUX010000005.1, 
CAUV020000007.1, CAUU020000009.1, CAVA010000006.1, CAUT020000006.1, 
CAUP020000008.1, CAUW010000006.1, CAUS020000010.1, and CAAH020000009.1 
(2, 31-33). Candidate primers and probes were selected using Primer-BLAST (34) and 
ProbePCR 2.5 (ELITech Group, Puteaux, France). The following programs were used to 
evaluate candidate primers for hairpin formation, dimerization, and annealing 
temperature: Multiple Primer Analyzer (ThermoFisher Scientific, Waltham, MA), 
AutoDimer (35), and PriDimerCheck (36). 
 
Sample Preparation 
The samples used in this study were clinical specimens received by ARUP 
Laboratories (Salt Lake City, UT). All clinical testing was completed and established 
specimen retention periods had expired before samples were used for validation purposes. 
All clinical samples were de-identified according to the Department of Health and 
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Human Services Safe-Harbor method and in accordance with the requirements of the 
University of Utah Institutional Review Board protocol regulating this study 
(IRB_00007275). 
Due to the rarity and fastidious growth requirements of T. whipplei, neither 
archived strains or previously positive patient material were available for the initial assay 
development and validation in 2015.  A custom plasmid referred to as T. whipplei control 
plasmid (TWCP) was purchased from Integrated DNA Technologies (Coralville, IA). 
This plasmid contains a single copy of the 7xRepeat and rpoB target sequences and was 
used as the spiking material to simulate positive samples in the majority of experiments 
with CSF, serum, plasma, and whole blood. The concentration of TWCP was determined 
by UV spectrophotometry prior to spiking. 
In late 2016, the T. whipplei strain CSURT0001 was obtained from the Collection 
de Souches de l’Unité des Rickettsies (Unité de Recherche sur les Maladies Infectieuses 
et Tropicales Émergentes, Marseille, France). The strain was maintained in culture as 
previously described (37). Briefly, the strain was cultured in DMEM/F12 media 
(ThermoFisher) supplemented with 10% fetal bovine serum (ThermoFisher), 1% L-
glutamine (ThermoFisher), and 1% nonessential amino acids (ThermoFisher). The 
culture was passaged weekly and monitored for growth by RT-PCR. The cultured 
bacteria (referred to herein as CSURT) were then spiked into negative samples to 
simulate positive samples, including all experiments involving frozen tissue. 
To generate T. whipplei positive formalin-fixed paraffin-embedded (FFPE) 
samples, cultured CSURT was pelleted by centrifugation then resuspended in 4% 
NuSieve GTG Agarose (Lonza, Basel, Switzerland) in 1X Tris-Borate-EDTA (ARUP 
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Laboratories) to create an approximately 200μL agarose plug. Plugs were submitted to 
the ARUP Histology Research department for formalin fixation and paraffin embedding. 
Fixation and embedding was performed on a Tissue-Tek VIP 6 Vacuum Infiltrator 
Processor (Sakura Finetek USA, Torrence, CA). 
Cross-reactivity of T. whipplei detection reagent was assessed by performing RT-
PCR with extracted nucleic acid from a panel microorganisms. These organisms were 
obtained from clinical isolates identified at ARUP Laboratories or from the American 
Type Culture Collection. 
 
Nucleic Acid Extraction 
Plasma, serum, CSF, and EDTA whole blood samples were extracted on a 
Chemagic MSM I instrument (PerkinElmer, Baesweiler, Germany) using the Chemagic 
Viral NA/gDNA kit (PerkinElmer). A volume of 200μL of each sample was mixed with 
the following kit reagents prior to loading on the instrument: 450μL of lysis buffer, 10μL 
of Proteinase K, and 4μL of poly(A) RNA. Samples were eluted in 80μL of elution 
buffer. T. whipplei positive samples were simulated by spiking negative samples with 
either TWCP or CSURT prior to extraction. 
Frozen tissue samples were extracted on a Maxwell 16 instrument (Promega, 
Madison, WI) using the Maxwell 16 Viral Total Nucleic Acid Purification kit (Promega). 
Prior to extraction, approximately 25mg of each tissue sample was minced with a 
disposable scalpel and incubated at 56°C for 10-20 minutes in 200μL of Lysis buffer and 
20μL of Proteinase K. Samples were eluted in 50μL of Nuclease-Free Water. T. whipplei 
positive samples were simulated by spiking with CSURT prior to the 56°C incubation. 
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FFPE tissue samples were extracted on a Maxwell 16 using the Maxwell 16 FFPE 
Tissue LEV DNA Purification kit (Promega). Prior to extraction, 10μm shavings were 
taken from FFPE blocks and incubated at 70°C for 60 minutes in 180μL of incubation 
buffer and 20μL Proteinase K. After incubation, 400μL of lysis buffer was added to each 
sample and samples were loaded onto the instrument. Samples were eluted in 50μL of 
elution buffer. Shavings from T. whipplei FFPE blocks were processed like normal 
samples until the end of the 60-minute incubation/digestion. After this incubation, the 
digested T. whipplei shavings were diluted in additional incubation buffer and spiked into 
patient samples immediately prior to the addition of lysis buffer.  
 
Internal, Negative, and Positive Controls 
All extractions were spiked with internal control nucleic acid prior to extraction to 
monitor extraction efficiency and detect any PCR inhibition. Extractions on the 
Chemagic MSM I were spiked with 1.2μL of RNA internal control and 0.872μL of DNA 
internal control per sample. Frozen tissue extractions were spiked with 2.18μL of DNA 
internal control and FFPE extractions were spiked with 0.545μL of DNA internal control 
prior to extraction. The negative and positive controls for both extraction methods were 
200μL of molecular biology grade (MBG) water (Quality Biological, Gaithersburg, MD) 
and 200μL of dilute TWCP, respectively. 
 
Limit of Detection Dilutions 
The limit of detection for each sample type was determined by spiking a negative 
sample with T. whipplei target sequence and creating a series of five-fold dilutions in the 
14 
 
specific sample matrix. CSF, whole blood, serum, and plasma samples were spiked with 
TWCP. Frozen tissues were digested with Proteinase K then spiked with CSURT and 
diluted in additional digested tissue to maintain the same concentration of tissue in each 
level of the dilution series. FFPE samples were also digested with Proteinase K then 
spiked with digested sections from an FFPE CSURT block. FFPE dilutions were made in 
additional digested FFPE tissue to maintain the concentration of FFPE tissue in each 
level of the dilution series. RT-PCR and dPCR were performed in parallel on FFPE 
samples to quantify the concentration of CSURT. 
 
Real-Time Polymerase Chain Reaction 
T. whipplei primers and probes were provided by ELITech Group and diluted to 
make a 20X Detection Reagent solution (Table 1). Pleiades probes were selected for the 
detection chemistry (38). These probes contain a minor groove binding protein (MGB) 
and bind to amplicon reversibly during thermal cycling to enable real-time detection and 
end-point melting analysis. The modified nucleotides 8-aza-7-deazaguanosine and 7-
hydroxybutynyl-2-amino-8-aza-7-deazaadenosine were included in probe sequences as 
indicated by an asterisk following the base in the written sequence. These bases stabilize 
probe-amplicon hybrids to increase the melting temperature (Tm) of the probe. 
Amplification reactions contained 10μL of 5X Custom ARUP Hot Start 
MasterMix (Promega), 8μL of 25mM MgCl2 (Promega), 2.5μL of 20X Detection 
Reagent, 0.5μL of AmpErase Uracil N-Glycosylase (ThermoFisher), 19μL of MBG 
water, and 10μL of extracted nucleic acid (Table 2). Amplification took place on a 





Digital Polymerase Chain Reaction 
dPCR with the QuantStudio 3D system was performed using a ProFlex 2x Flat 
thermal cycler, QuantStudio 3D chip reader, Digital PCR Chip Loader, Digital PCR 20K 
v2 Chip Kit, and Digital PCR v2 Master Mix (ThermoFisher). Because this system is 
designed to use TaqMan probes, TaqMan versions of Tw7x-AP525 and TwrpoB-FAM 
were made by removing the MGB protein (ELITech). Primers and probes were used in 
the same concentration as for RT-PCR. Amplification reactions were made by combining 
17.4μL of Digital PCR Master Mix, 1.74μL of 20X Detection reagent, 3.66μL of MBG 
water, and 12μL of extracted nucleic acid. Two chips were loaded with 14.5μL each of 
the amplification reaction. The manufacturer-recommended cycling conditions were used 
with a modified annealing temperature of 56°C. dPCR with the RainDrop Plus system 
(RainDance Technologies, Billerica, MA) was performed using 12.5μL of TaqMan 
Genotyping Master Mix (ThermoFisher), 1μL of detection reagent, 7.5μL of extracted 
nucleic acid, and manufacturer-recommended amounts of kit reagents to produce a 25μL 
reaction for partitioning. The manufacturer-recommended cycling conditions were used 
with a modified annealing temperature of 56°C. 
The 1st WHO International Standard for EBV and the 1st WHO International 
Standard for HDV were obtained from the WHO and were used in EBV and HDV dPCR 
experiments. Extraction was performed on the Chemagic MSM I in the same manner as 
T. whipplei samples. Reverse transcription of extracted HDV RNA was performed using 
a Superscript II kit and random hexamer primers (ThermoFisher) as shown in Table 4. 
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Synthesis was performed by a 65°C incubation of extracted RNA for five minutes 
followed by addition of Superscript master mix then 25°C for 10 minutes, 45°C for 30 
minutes, and 70°C for 15 minutes. 
HDV and EBV dPCR experiments on the QuantStudio 3D used the same 
amplification volumes and conditions as T. whipplei. TaqMan probes for EBV were 
provided by ELITech Group in addition to a Pleiades version of the EBV probe with the 
same sequence. HDV primers were purchased from Integrated DNA Technologies and 
probes from BioSearch Technologies (Petaluma, CA). Detection reagent sequences for 
EBV and HDV are provided in Table 5. A second set of EBV detection reagents targeting 
a different sequence were also provided by ELITech based on a previously described 



























Table 1: List of T. whipplei primer and probe sequences and concentrations. 
Primer/Probe 
Name 
Sequence (5’ → 3’)a 
20X 
Conc. 
Tw7xF-L GAGAAGGTGTATCTGGAGTTTCTGAG 5μM 
Tw7xR-E TGTTCCCATACACAAACAGATAGATAAC 20μM 
TwrpoBF-L GGTACAAAGTAAATCGCAAACTCGG 5μM 
TwrpoBR-E CGAATTGTTGCGATAATATCCGACCT 20μM 
E6132L CTGCACGGACCAGTTACTTTACG 6μM 
E6132E CTCATTTTTTCTACCGGAGATCTTGT 2μM 
Tw7x-AP525 MGB-AP525-GATGGTA*TGTCTGAGAGA-NFQ 4μM 
TwrpoB-FAM MGB-FAM-GATGTTGA*TCCAACTCG-NFQ 4μM 
E6132-AP642-4 MGB-AP642-G*AATGCGGTACGTGGTCC-NFQ 4μM 
a An asterisk indicates that the previous nucleotide has a modified base.  






Table 2: Reagents and volumes used for RT-PCR 
Reagent Volume Per Reaction 
5X Custom ARUP Hot Start Master Mix 10μL 
25mM MgCl2 8μL 
20X Detection Reagent 2.5μL 
UNG 0.5μL 
MBG Water 19μL 






Table 3: RT-PCR thermal cycling conditions 
Cycles Temperature Time 
1 
50°C 10 minutes 
95°C 2 minutes 
50 
95°C 5 seconds 
56°C 20 seconds 
76°C 20 seconds 
1 
95°C 15 seconds 
45°C 15 seconds 










Table 4: HDV reverse transcription reagents and volumes 
Reagent Volume Per Reaction 
5x Superscript II First Strand Buffer 4.0μL 
0.1M DTT 1.0μL 
Superscript II Reverse Transciption Enzyme 0.5μL 
RNaseOUT Recombinant RNase Inhibitor 0.5μL 
15mM dNTPs 2.0μL 







Table 5: EBV and HDV primer and probe sequences 
Primer/Probe 
Name 
Sequence (5’-3’)a 20X Conc. 
EBV-F AATAAATCATAACGGTTAATCCGATCTGGTCGCA 20μM 
EBV-R AATAAATCATAAGAACCTGGTCG*TCCTTTG 5μM 
EBV Probe MGB-FAM-G*TACG*AGTG*CCTG*CG*A-NFQ 12μM 
HDV-879F GGTGGAGATGCCATGCCG 10μM 
HDV-961R CCCAGTGAATAAAGCGGGTTTCC 10μM 













a An asterisk indicates that the previous nucleotide has a modified base.  
MGB = minor groove binding protein; NFQ = non-fluorescent quencher; BHQ-1 = 






Assay Design and Specificity 
Two regions of the T. whipplei genome were selected as targets for RT-PCR: the 
DNA-directed RNA polymerase subunit beta (rpoB) gene and a unique repeat sequence 
that is present seven times in the T. whipplei genome (7xRepeat). The 7xRepeat target 
was selected for the increase in sensitivity provided by repeat sequences. However, these 
repeat regions are poorly represented in sequence databases, limiting our knowledge of 
nucleotide variants that could interfere with primer or probe binding. The rpoB gene was 
selected as a second target to complement 7xRepeat because it is better represented in 
sequence databases.  
Primer-BLAST analysis of these regions provided candidate primer sequences, 
including the primers Tw7xF-L, Tw7xR-E, TwrpoBF-L, and TwrpoBR-E, producing 
amplicons 78 and 85 base pairs in length for 7xRepeat and rpoB, respectively. Analysis 
of these primers with AutoDimer and Multiple Primer Analyzer predicted no primer 
dimerization or hairpin formation. Some minor interactions were predicted by 
PriDimerCheck but were too weak to have an impact in the temperature range of PCR. 
Additional Primer-BLAST queries with these primers predicted no cross-reactivity with 
other bacteria, viruses, parasites, or the human genome. The 7xRepeat and rpoB amplicon 
sequences produced with theses primers were analyzed using ProbePCR 2.5 to generate 
candidate probe sequences. The probes Tw7x-AP525 and TwrpoB-FAM were selected 
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based on analysis with AutoDimer, Multiple Primer Analyzer, and PriDimerCheck, 
which did not predict hairpin or dimer formation.  
To determine the impact of 7xRepeat and rpoB co-amplification on PCR 
efficiency, TWCP was amplified with 7xRepeat reagents only, rpoB reagents only, and 
with both reagents combined. The average change in crossing threshold (CT) with 
combined reagents compared to single target reagents was +0.8 CTs for 7xRepeat (n = 6; 
SD = 0.7; p = 0.037) and +0.2 CTs for rpoB (n = 6, SD = 0.4; p = 0.27). Next, primers 
and probe specific for the DNA internal control were combined with 7xRepeat and rpoB 
reagents and TWCP was amplified. The average change in CT with the addition of 
internal control reagents was -0.3 CTs for 7xRepeat (n = 6, SD = 0.5; p = 0.26) and by -
0.2 CTs for rpoB (n = 6, SD = 0.6; p = 0.57). Post-PCR melting analysis produced a Tm 
of 62.1°C (± 0.5°C) for 7xRepeat and 65.9°C (± 0.9°C) for rpoB. The combination of 
7xRepeat, rpoB, and internal control reagents will subsequently be referred to as T. 
whipplei detection reagent.  
To confirm the specificity of T. whipplei detection reagent, a panel of bacteria and 
other pathogens were tested for cross-reactivity (Table 6). Organisms were selected based 
on their phylogenetic relationship to T. whipplei, potential presence in sample types 
submitted for T. whipplei testing, and the presence of testing for the agent within the 
same laboratory space at ARUP. Of the 78 organisms tested, none produced a CT for 






Assay Limit of Detection 
Several sample types of clinical interest were selected for validation including 
CSF, EDTA whole blood, frozen tissue, and FFPE tissue. Serum and EDTA plasma were 
also validated, though there is less evidence to support clinical testing of these sample 
types. Each sample type was spiked with T. whipplei target sequence and a five-fold 
dilution series was made in the specific specimen matrix. Each level in the dilution series 
was extracted in triplicate and each extraction was amplified in duplicate, providing a 
total of six replicates at each level. The lowest concentration where all six replicates were 
detected was defined as the limit of detection for the sample type (Table 7). 
For all specimen types except FFPE tissue, the quantity of T. whipplei target 
sequence spiked was determined prior to spiking and the concentration in each level of 
the dilution series was then calculated. For FFPE tissue, dPCR on the most concentrated 
FFPE sample in the dilution series indicated that 31,159 copies of rpoB (n = 2; 95% C.I. 
of 30,299 – 32,042) and 204,030 copies of 7xRepeat (n = 2; 95% C.I of 201,173 – 
206,930) had been spiked into the sample, with a 7xRepeat to rpoB copy ratio of 6.5. The 
next level in the dilution series yielded 6,453 copies of rpoB (n = 2; 95% C.I. of 6,088 – 
6,832) and 41,925 copies of 7xRepeat (n = 2; 95% C.I. of 40,931 – 42,943), with a 
7xRepeat to rpoB copy ratio of 6.5. Target copy number in subsequent levels in the 
dilution series were calculated from these values. 
 
Assay Accuracy Validation 
For each sample type, the accuracy of the assay was determined by testing ten 
negative samples and thirty samples that had been spiked with T. whipplei target 
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sequence. For CSF, whole blood, serum, and plasma, the spiking material was TWCP 
while frozen tissue and FFPE were spiked with CSURT. Samples were spiked with either 
low, medium, or high concentrations of TWCP or CSURT, with at least ten samples 
spiked within one log of the limit of the detection for the specific sample type (Table 8). 
No negative samples produced CTs for 7xRepeat or rpoB in any sample type. The 
average internal control CT for these samples is shown in Table 8. All spiked samples 
tested positive for CSF, frozen tissue, FFPE, serum, and plasma. Twenty-eight of the 
thirty spiked whole blood samples also tested positive as expected while two others, 
HB14 and HB17, tested negative for T. whipplei. 
HB17 did not produce an internal control CT on initial testing. When RT-PCR 
was repeated on the same extracted nucleic acid, HB17 remained negative for both T. 
whipplei targets but produced a CT of 42.9 for the internal control. HB14 had an internal 
control CT of 36.4 and when RT-PCR was repeated on the same extracted nucleic acid 
produced a CT of 37.9 for 7xRepeat and 38.6 for rpoB. HB17 and HB14 had been spiked 
with 800 copies of TWCP. Two additional whole blood samples were spiked with 800 
copies of TWCP to provide a total of thirty unambiguous positive whole blood samples. 
Both of these produced CTs for 7xRepeat and rpoB as expected. 
 
Assay Reproducibility 
The reproducibility of positive results within a single extraction run was 
determined for each sample type. Three samples of each sample type were spiked with 
low, medium, or high amounts of TWCP or CSURT then extracted in triplicate on the 
same extraction run and amplified together (Table 9). One low concentration whole blood 
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replicate did not produce a CT for 7xRepeat or rpoB. The internal control for this 
replicate was 45.4 on initial testing. Re-amplification on the same extracted nucleic acid 
was again negative for 7xRepeat and rpoB and produced an internal control CT of 45.0. 
The reproducibility of positive results between extraction runs was also 
determined. Three samples of each sample type were spiked with low, medium, or high 
amounts of TWCP or CSURT then extracted on three separate extraction runs and 
amplified on separate amplification runs (Table 10).  One low concentration FFPE 
replicate produced a CT of 36.9 for 7xRepeat but none for rpoB on initial testing. This 
sample was re-amplified and produced a 7xRepeat CT of 36.2 and rpoB CT of 40.5. 
These results were used in calculating the statistics in Table 10. 
 
Analyte Stability 
To estimate the stability of T. whipplei in CSF, serum, plasma, and whole blood, 
samples were spiked with CSURT then split into several aliquots. One aliquot was 
immediately placed at -70°C to provide a baseline reference. The remaining aliquots were 
placed at room temperature (RT), 4°C, or -20°C and transferred to -70°C at specific time 
points. For tissue, a tissue sample was split into three equal sections of approximately 
25mg and each section was spiked with equal amounts of CSURT. Upon completion of 
all time points, samples were thawed and extracted together. The change in CT from 
baseline to each time point was calculated and are shown in by sample type in Tables 11-
15. A minus sign indicates the CT was lower at the indicated time point than at baseline.  
For each temperature and sample type, the longest time point with an increase in 
CT less than 1.5 for both targets was defined as the maximum stability and is highlighted 
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in each table. Additional time points were measured in a second experiment with plasma 
and whole blood due to poor stability at the one day time point for RT plasma, RT whole 
blood, and whole blood stored at 4°C (Tables 13 and 14). The stability of T. whipplei in 
tissue was not evaluated at room temperature or 4°C based on a historical precedent in 
the Molecular Infectious Disease department at ARUP of only testing tissue that has been 
transported frozen.  
The stability in FFPE samples was estimated by taking three sections from a 
manufactured FFPE block made with CSURT. The first was tested immediately, the 
second after two weeks at 4°C, and the third after 30 days at room temperature. Results 
are shown in Table 16. Based on these results and the known stability of DNA in FFPE 
samples, these samples will be considered acceptable for testing regardless of collection 
time. 
 
Clinical Testing Experience 
The T. whipplei assay was made available to ARUP clients in April 2016 for CSF, 
serum, plasma, and whole blood sample types. The validation of tissue and FFPE samples 
is currently undergoing standard review procedures and will be available in the near 
future. Eight-hundred and ninety-seven samples were submitted for testing between April 
2016 and April 2017, producing positive results for three male patients 40-75 years of 
age. The positive results were obtained in whole blood, CSF, and vitreous fluid, the last 
of which has not been validated for this assay. An FFPE duodenum tissue from one of 
these patients was positive for T. whipplei when tested at another commercial reference 
laboratory. This FFPE block was also tested at ARUP and T. whipplei was detected with 
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a 7xRepeat CT of 23.1 and an rpoB CT of 24.9.  
 
International Standard Evaluation 
To better characterize the WHO International Standards for EBV and HDV, 
dPCR was used to estimate the viral copy number in each standard. Fresh aliquots of both 
standards were prepared and evaluated by dPCR. Both standards were evaluated with two 
different primer and probe sets. Only a single extraction of HDV standard was available 
for testing (Table 17) while two extractions performed at different times were available 































Table 6: Organisms tested for cross-reactivity with T. whipplei detection reagents 
Human metapneumovirus Influenza A Giardia species 
Borrelia burgdorferi Influenza B Nocardia asteroides 
Bordetella pertussis 2009-H1N1 Propionibacterium acnes 
Bordetella parapertussis Parainfluenza 1 Rhodococcus equi 
Haemophilus parainfluenzae Parainfluenza 2 Cyclospora species 
Streptococcus anginosus group Parainfluenza 3 Corynebacterium striatum 
Cryptosporidium species Parechovirus 2 Neisseria lactamica 
Campylobacter hyointestinalis Parechovirus 3 Staphylococcus epidermidis 
Campylobacter coli RSV Escherichia coli 
Campylobacter lari SARS RNA Neisseria meningitidis 
Campylobacter jejuni West Nile virus Pseudomonas aeruginosa 
Camplyobacter upsaliensis Parvovirus B-19 Moraxella catarrhalis 
Campylobacter urealyticus JC virus Staphylococcus aureus 
Mycoplasma pneumoniae BK virus Haemophilus influenzae 
Chlamydophila pneumoniae CMV Streptococcus pneumoniae 
Bartonella henselae EBV Streptococcus pyogenes 
Legionella pneumophila VZV Dientamoeba fragilis 
Legionella micdadei Enterovirus 71 Entamoeba histolytica 
Actinomyces israelii Shiga toxin 1 Salmonella species 
Actinomyces odontolyticus Shiga toxin 2 Human Herpesvirus 6A 
Tsukamurella tyrosinosolvens Bacillus cereus Human Herpesvirus 6B 
Bacteroides fragilis Shigella dysentariae Herpes Simplex virus 
Candida albicans Shigella boydii Norovirus genogroup I 
Citrobacter freundii Shigella sonnei Norovirus genogroup II 
Enterobacter aerogenes Shigella flexneri Coxsackievirus A9 
Enterococcus faecalis Toxoplasma gondii Coxsackievirus A16 





Table 7: Limit of detection by sample type 
Sample Type 
7xRepeat copies  
per PCR reaction 
rpoB copies  
per PCR reaction 
Copies/mL  
of sample 
CSFa 100 100 4,000 
Seruma 20 20 800 
Plasmaa 100 100 4,000 
Whole Blooda 20 20 800 
Frozen Tissueb 4 4 N/A 
FFPEb 10 50 N/A 
a Spiked with TWCP 















Range (St. Dev) 
CSFa 150 – 50,000 26.1 – 36.6 26.2 – 37.0 35.1 (0.8) 
Seruma 50 – 50,000 26.4 – 37.5 26.5 – 37.5 35.2 (0.7) 
Plasmaa 150 – 50,000 27.4 – 36.2 27.5 – 36.4 35.7 (0.6) 
Whole Blooda 50 – 50,000 28.0 – 38.9 27.9 – 38.9 36.5 (0.5) 
Frozen Tissueb 20 – >200 25.4 – 32.8 28.1 – 34.8 32.6 (0.6) 
FFPEb 40 – >1,000 18.9 – 37.5 21.0 – 39.6 36.2 (0.5) 
a Copies given in TWCP copies per 50μL RT-PCR reaction 








7xRepeat CT  
St. Dev. (%CoV) 
rpoB CT 
St. Dev. (%CoV) 
CSFa 
Low 0.85 (2.35) 0.80 (2.2) 
Medium 0.29 (0.9) 0.30 (0.9) 
High 0.19 (0.7) 0.20 (0.7) 
Seruma 
Low 0.05 (0.1) 0.02 (0.1) 
Medium 0.16 (0.5) 0.17 (0.5) 
High 0.25 (0.9) 0.23 (0.8) 
Plasmaa 
Low 0.31 (0.9) 0.23 (0.6) 
Medium 0.06 (0.2) 0.06 (0.2) 
High 0.15 (0.5) 0.15 (0.5) 
Whole Blooda 
Low - - 
Medium 0.09 (0.3) 0.12 (0.4) 
High 0.30 (1.1) 0.22 (0.8) 
Frozen Tissueb 
Low 0.09 (0.3) 0.15 (0.5) 
Medium 0.20 (0.7) 0.32 (1.0) 
High 0.19 (0.7) 0.26 (0.9) 
FFPEb 
Low 0.07 (0.2) 0.15 (0.5) 
Medium 0.44 (1.4) 0.52 (1.6) 
High 0.05 (0.2) 0.16 (0.5) 
a Spiked with TWCP 














7xRepeat CT  
St. Dev. (%CoV) 
rpoB CT 
St. Dev. (%CoV) 
CSFa 
Low 0.15 (0.4) 0.20 (0.6) 
Medium 0.42 (1.3) 0.46 (1.5) 
High 0.24 (0.8) 0.33 (1.2) 
Seruma 
Low 0.57 (1.6) 0.70 (2.0) 
Medium 0.07 (0.2) 0.18 (0.6) 
High 0.23 (0.8) 0.27 (1.0) 
Plasmaa 
Low 0.23 (0.7) 0.30 (0.9) 
Medium 0.15 (0.5) 0.14 (0.4) 
High 0.30 (1.0) 0.28 (1.0) 
Whole Blooda 
Low 0.78 (2.1) 0.71 (2.0) 
Medium 0.67 (2.1) 0.58 (1.8) 
High 0.13 (0.4) 0.23 (0.8) 
Frozen Tissueb 
Low 0.20 (0.6) 0.17 (0.5) 
Medium 0.24 (0.9) 0.27 (0.9) 
High 0.16 (0.6) 0.19 (0.6) 
FFPEb 
Low 0.95 (2.6) 1.9 (4.9) 
Medium 1.23 (3.9) 1.17 (3.5) 
High 0.86 (3.0) 0.61 (2.0) 
a Spiked with TWCP 





Table 11: Stability in CSF 
Sample  7xRepeat CT 7xRepeat Δ CT  rpoB CT rpoB Δ CT 
CSF Baseline 24.69 N/A 26.38 N/A 
CSF 1D RT 25.13 0.44 26.89 0.51 
CSF 3D RT 25.38 0.69 27.18 0.80 
CSF 5D RT 24.64 -0.05 26.59 0.21 
CSF 7D RT 24.55 -0.14 26.41 0.03 
CSF 5D 4°C 24.95 0.26 26.74 0.37 
CSF 7D 4°C 24.95 0.26 26.64 0.26 
CSF 14D 4°C 25.25 0.57 26.96 0.58 
CSF 14D -20°C 22.87 -1.82 24.52 -1.86 











Table 12: Stability in serum 
Sample  7xRepeat CT 7xRepeat Δ CT  rpoB CT rpoB Δ CT 
Serum Baseline 25.73 N/A 27.31 N/A 
Serum 1D RT 26.44 0.71 27.96 0.65 
Serum 3D RT 27.08 1.35 28.93 1.62 
Serum 5D RT 27.21 1.48 28.96 1.65 
Serum 7D RT 27.96 2.23 29.67 2.36 
Serum 5D 4°C 25.24 -0.49 26.98 -0.33 
Serum 7D 4°C 25.64 -0.09 27.50 0.19 
Serum 14D 4°C 26.45 0.72 28.21 0.90 
Serum 14D -20°C 24.38 -1.35 26.31 -1.00 






Table 13: Stability in plasma 
Sample  7xRepeat CT 7xRepeat Δ CT  rpoB CT rpoB Δ CT 
Plasma Baseline 23.00 N/A 25.00 N/A 
Plasma 1D RT 25.09 2.09 26.91 1.91 
Plasma 3D RT 25.20 2.20 27.08 2.08 
Plasma 5D RT 25.89 2.89 28.13 3.13 
Plasma 7D RT 25.97 2.97 27.74 2.74 
Plasma 5D 4°C 23.38 0.38 25.10 0.10 
Plasma 7D 4°C 23.40 0.39 25.17 0.17 
Plasma 14D 4°C 23.42 0.41 25.21 0.21 
Plasma 14D -20°C 23.47 0.46 25.30 0.30 
Plasma 30D -20°C 24.12 1.12 25.99 0.99 
     
Plasma Baseline 23.97 N/A 25.79 N/A 
Plasma 2Hr RT 24.91 0.94 26.84 1.05 
Plasma 4Hr RT 24.72 0.75 26.58 0.80 









Table 14: Stability in whole blood 
Sample 7xRepeat CT 7xRepeat Δ CT rpoB CT rpoB Δ CT 
WB Baseline 21.72 N/A 23.59 N/A 
WB 1D RT 23.93 2.21 26.08 2.48 
WB 3D RT 24.48 2.76 26.38 2.79 
WB 5D RT 24.26 2.53 26.08 2.49 
WB 7D RT 24.88 3.16 26.50 2.91 
WB 5D 4°C 23.81 2.09 25.74 2.15 
WB 7D 4°C 24.04 2.32 26.17 2.58 
WB 14D 4°C 22.71 0.99 24.59 1.00 
WB 14D -20°C 21.58 -0.14 23.62 0.02 
WB 30D -20°C 21.34 -0.39 23.47 -0.12 
     
WB Baseline 22.57 N/A 24.70 N/A 
WB 2Hr RT 22.90 0.33 24.74 0.04 
WB 4Hr RT 22.86 0.29 24.71 0.01 
WB 8Hr RT 22.89 0.32 24.77 0.07 
WB 2Hr 4°C 21.70 -0.87 23.55 -1.15 
WB 4Hr 4°C 21.78 -0.79 23.53 -1.17 





Table 15: Stability in tissue 
Sample  7xRepeat CT 7xRepeat Δ CT  rpoB CT rpoB Δ CT 
Tissue Baseline 23.65 N/A 25.91 N/A 
Tissue 14D -20°C 23.60 0.05 25.60 0.31 





Table 16: FFPE T. whipplei stability 
Sample  7xRepeat CT 7xRepeat Δ CT  rpoB CT rpoB Δ CT 
FFPE Baseline 19.40 N/A 21.92 N/A 
FFPE 14D 4°C 17.96 -1.09 20.55 -1.38 






















Amplicon 1 4 2.80 (2.75 – 2.85) 4.9 













Amplicon 1 4 2.69 (2.66 – 2.72) 1.9 
Amplicon 1a 4 2.62 (2.59 – 2.65) 1.9 
Amplicon 2 4 2.53 (2.51 – 2.56) 2.0 
2 
Amplicon 1 3 3.11 (3.07 – 3.16) 1.6 
Amplicon 2 3 2.85 (2.80 – 2.90) 1.8 
2b 
Amplicon 1 1 2.69 (2.66 – 2.72) 1.9 
Amplicon 2 1 2.62 (2.60 –2.65) 1.9 
        a Pleiades probe format 








This thesis describes the development of a clinical RT-PCR assay for the 
detection of T. whipplei. One of the challenges in designing a molecular assay for rare 
and less-studied organisms is the lack of available sequence data. Only two complete 
genomes of T. whipplei have been published to date, though an additional seventeen are 
listed in NCBI’s Genome database at various stages of completion. These two genomes 
and one partially sequenced isolate were the only sequences available for the 7xRepeat 
region, providing coverage of 15 individual repeats. This limited representation was a 
major factor in the decision to include rpoB as a second target in the assay, which had 
sequences available from twenty-one different isolates of T. whipplei. Targeting both 
genes decreases the likelihood of a false negative result due to nucleotide variants under 
primer or probe binding sites. Additionally, it has been suggested that positive RT-PCR 
results for T. whipplei should be confirmed by follow-up testing of a different target 
sequence (40). Combining detection of rpoB and 7xRepeat in a single duplex assay 
accomplishes this without the need for a second amplification reaction, reducing the time 
needed to report positive results.  
The lack of patient samples positive for T. whipplei and the inability to purchase 
the organism from repositories in the United States made it necessary to use a plasmid to 
simulate positive samples for several experiments. While this makes it possible to 




replacement for actual organism. Acquiring CSURT made it possible to improve the 
assay validation by more accurately simulating a positive patient. To the author’s 
knowledge, this assay is the only assay available in the United States which has been 
validated using cultured T. whipplei.  
The limit of detection for all sample types was below 100 copies per RT-PCR 
reaction for both targets, with frozen tissue having the lowest limit of detection of four 
copies per reaction. This observation is consistent with previous experience at ARUP 
extracting tissue using the Maxwell 16 instrument, which tends to provide higher purity 
DNA and lead to earlier CTs in RT-PCR relative to the Chemagic MSM I (data not 
shown). Greater sensitivity is especially beneficial with tissue since testing duodenum 
biopsies is standard practice in diagnosing WD.  
The accuracy of the assay was 100% in each sample type with the exception of 
two whole blood samples which tested negative despite being spiked with TWCP prior to 
extraction. No internal control CT was produced from the extraction of sample HB17 
during initial testing and insufficient sample remained to perform an additional 
extraction. Re-amplification of the initial extraction produced an internal control CT of 
42.9. The cutoff for a valid internal control in a negative sample used in the ARUP 
clinical laboratories is three standard deviations from the mean internal control CTs. The 
HB17 internal control value is 6.4 cycles (>12 St. Dev.) later than the average internal 
control CT of 36.5 calculated from all negative whole blood samples, suggesting that 
PCR is not performing optimally. This result was likely due to poor extraction or the 
presence of an inhibitory substance in the sample that could not be removed by the 




submitted to ARUP for T. whipplei testing where the internal control produced a CT 
outside a three standard deviation range. Both of these samples were re-extracted and 
tested again before being reported as indeterminate. These results indicate that the 
internal control is performing as expected to prevent potential false negatives from being 
reported when poor extraction or inhibition are the cause of a negative result. 
The initial detection failure in HB14 remains unclear as the internal control result 
was normal and re-amplification of the same extracted material was positive for both T. 
whipplei targets. HB14 was spiked with approximately 800 copies of TWCP prior to 
extraction, roughly five times the limit of detection in whole blood. This makes the 
probability of failure due to sampling error very low. The lack of amplification may be 
due to a mistake during RT-PCR setup, though laboratory workflow is designed to 
minimize the possibility of such errors. While not used during this study, automated 
liquid handlers perform all RT-PCR setup for clinical testing to provide consistency and 
accuracy.  
The reproducibility of positive CTs in the assay was good, with a coefficient of 
variance less than 5% in all cases. Results for FFPE samples were the most variable. One 
inter-run reproducibility sample initially tested positive for 7xRepeat but was negative for 
rpoB. A high CT for rpoB was produced when the same extracted material was re-
amplified. This sample was spiked with approximately 100 CSURT genomes which is 
two-fold higher than the limit of detection for rpoB in FFPE samples. The greater 
variation observed in FFPE samples particularly at low concentrations is the most likely 
explanation for the initial negative rpoB result. 




long stability of up to seven days at room temperature, while serum was only stable for 
twenty-four hours and both plasma and whole blood for eight hours. The refrigerated 
stability was two weeks in these sample types with the exception of whole blood which 
was stable for eight hours. This difference in stability is important information to provide 
clinicians and hospital staff in specimen collection guidelines, particularly with whole 
blood and CSF which are both clinically relevant sample types but have very different 
stability profiles. Whole blood samples are frequently transported at 4°C for many tests, 
but these data indicate that whole blood samples for T. whipplei testing should be 
submitted frozen. In general, the change in CT was the smallest with frozen aliquots for 
all sample types. The decision to use -70°C as a baseline temperature was made to enable 
a data-based validation of analyte stability at -20°C for regulatory reasons. The author 
acknowledges that the difference in stability between these temperatures over small time 
periods should be negligible. 
Testing the performance of an assay on FFPE samples presents many challenges. 
Formalin-fixation and paraffin-embedding is known to fragment nucleic acids and limit 
the success of PCR, particularly with amplicons greater than 250 basepairs (41). 
Infectious disease assay validations for this sample type often mix cultured pathogens 
with FFPE tissue shavings, even though the pathogen has not been through the fixation 
and embedding process. While this method simplifies the validation process, it can lead 
to inaccurate results that overestimate the sensitivity of the assay because the target 
nucleic acid has not been exposed to fixatives and remains undamaged. Spiking tissues 
with cultured organism prior to fixation and embedding is also a poor substitute as most 




organism of interest which are then used to spike validation samples provides a more 
accurate, though still imperfect, simulation of true positive patient samples. This 
validation demonstrates the relative ease with which cultured bacteria can be suspended 
in agarose and processed similar to tissues to create FFPE blocks.  
A limitation to spiking FFPE samples this way is that the amount of organism 
present in a shaving cannot be known at the time spiking is performed. This necessitates 
using dPCR to quantify the organism postextraction in experiments where quantity is 
important, such as limit of detection experiments. FFPE samples contain different 
amounts of tissue and organism in each plane within the FFPE block, making any 
quantity determined prior to fixation and embedding irrelevant. This also prevents the 
creation of an FFPE standard curve for quantification since the concentration could not 
be maintained throughout the preparation process, making dPCR the most feasible 
method for quantification with FFPE samples. A weakness of this method is that only the 
concentration of target sequence present in the elution can be determined, not the actual 
concentration spiked into the extraction.  Thus, any loss during extraction is not 
accounted for.  
dPCR analysis of the WHO 1st International Standard for EBV showed that the 
concentration is between 2.5 and 3.2 million copies per milliliter, with an IU to copy ratio 
between 1.6 and 2.0. This was confirmed using two different dPCR platforms and two 
different target sequences. As with any reference standard, there is a limited supply and 
limited shelf-life for WHO international standards. To reduce consumption of the primary 
standard, laboratories use secondary commercial standards which were calibrated to the 




secondary standards for the same virus have been shown to have up to a ten-fold 
difference in results (42). Defining WHO standards in terms of copies instead of IUs may 
make it easier to reproduce it in secondary commercial form. dPCR is one tool for doing 
this.  
Other complications arise from the target sequence chosen for an assay, which 
varies widely between clinical laboratories for many pathogens, including EBV. Next-
generation sequencing of the recently released WHO standard for JC virus showed 
significant copy number variation between different regions of the viral genome due to 
various deletions (43). This can introduce systematic error between assays if they target 
regions with a different copy number but base their standard curve off of the same 
concentration of IUs. This problem cannot be addressed by dPCR alone either, which 
would accurately quantify the copy number of the sequence targeted in the dPCR assay 
but would not account for the copy number variation at other sites. These findings 
suggest that more thorough evaluation of WHO international standards and commercial 
secondary standards is needed before they are made available. Next-generation 
sequencing of standards and definition of standards in copy number instead of IUs are 
two steps that could aid laboratories in identifying potential problems during assay design 
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